TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “hold” rating reiterated by analysts at TD Cowen in a report released on Monday,Benzinga reports.

SPRO has been the topic of several other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. HC Wainwright cut their target price on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, November 4th.

Spero Therapeutics Stock Up 1.8 %

Shares of SPRO stock opened at $1.16 on Monday. The stock’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $1.36. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89. The firm has a market capitalization of $63.24 million, a P/E ratio of 16.57 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors have recently modified their holdings of SPRO. Acadian Asset Management LLC grew its holdings in shares of Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after acquiring an additional 418,742 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after acquiring an additional 121,492 shares in the last quarter. Virtu Financial LLC bought a new position in Spero Therapeutics during the first quarter valued at $31,000. Murchinson Ltd. grew its holdings in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the period. 25.60% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.